BUND FINANCE

BUND FINANCE › Stocks › TAK

Takeda Pharmaceutical Company Limited (TAK)

NYSE · Stock price, chart and technical analysis

US$21.27-0.3700 (-1.71%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$21.64
OpenUS$21.39
Day rangeUS$21.24 – US$21.62
52-week rangeUS$14.01 – US$21.86
Market capUS$67.96B
Volume3.42M
50-day averageUS$19.53
200-day averageUS$17.82
Beta0.09
Last dividend per shareUS$0.7053

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueJPY 3.57TJPY 4.03TJPY 4.26TJPY 4.58TJPY 4.78T
Net incomeJPY 230.1BJPY 317.0BJPY 144.1BJPY 107.9BJPY 203.3B
EPS (diluted)72.94100.9745.5833.6263.91
Gross margin69.0%69.1%66.4%65.5%51.1%
Operating margin12.9%12.2%5.0%7.5%12.0%
Net margin6.5%7.9%3.4%2.4%4.3%
Free cash flowJPY 937.1BJPY 343.5BJPY 235.6BJPY 677.6BJPY 626.8B
Total debtJPY 4.35TJPY 4.38TJPY 4.84TJPY 4.52TJPY 4.90T
CashJPY 849.7BJPY 533.5BJPY 457.8BJPY 385.1BJPY 597.6B

Compound annual growth: revenue 7.6% · net income -3.0% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E—40.3x27.1x
EV / EBITDA—8.8x16.5x
Operating margin13.7%—3.6%
Net margin8.2%—-0.0%
Debt / equity1.06—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation. The company reports in another currency: amounts are shown in that currency.

About Takeda Pharmaceutical Company Limited

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryJP
CEOJulie So-Young Kim
Employees47,029
IPO date2010-01-05

Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreemen…

www.takeda.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice